Latest News

Gedatolisib plus fulvestrant, with or without palbociclib, boosts PFS in HR+/HER2− PIK3CA WT breast cancer after CDK4/6.

IASLC TTLC 2026 spotlights patient voices, ctDNA MRD, EGFR co-mutations, and ADCs—plus real-world gaps in testing and multidisciplinary lung care.

Ipsen pulls Tazverik worldwide after SYMPHONY-1 flags secondary blood cancer risk, halting trials and access programs and moving patients to standard care.

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

How GLP-1 weight-loss drugs fit after breast cancer: emerging survival hints, new ESMO cautions during chemo, and smart tapering to avoid rebound.

See how breast cancer endocrine and targeted drugs inform endometrial and ovarian care—tamoxifen, CDK4/6 combos, and T-DXd.

The CYTOSHRINK trial showed that incorporating stereotactic body radiation therapy (SBRT) with ipilimumab and nivolumab did not enhance progression-free survival and resulted in a shorter median PFS compared to immunotherapy alone for advanced renal cell carcinoma.

Long-term CheckMate 9ER results show deeper tumor shrinkage with cabozantinib plus nivolumab predicts longer survival and durable responses in advanced renal cell carcinoma.

An interview with Joshua Reuss, MD, thoracic medical oncologist at Georgetown University and co-author of the guidelines.

Academic centers are associated with greater biliary tract cancer surgery success while minority patients and nonacademic care face gaps, urging better resource allocation.

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

A supplemental Biologics License Application has been submitted for nogapendekin alfa inbakicept-pmln (Anktiva) plus BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors.

Results from the 992-patient study will be presented at an upcoming medical meeting; FDA review of giredestrant is ongoing based on data from the positive evERA trial.

Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.

The addition of the CELMoD mezigdomide to carfilzomib and dexamethasone led to progression-free survival improvement in relapsed/refractory multiple myeloma.

Compare T-DXd, sacituzumab, and dato-DXd in HR+ metastatic breast cancer—key trial results, side effects, and sequencing insights.

PIM-1 kinase inhibitors in myelofibrosis offer new targets to overcome relapsed and refractory disease.

ctDNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA drops predict longer PFS.

FDA grants priority review to T-DXd for high-risk HER2-positive early breast cancer with residual disease, after trial shows markedly better recurrence-free survival than T-DM1.

New data push ADCs earlier, reshaping HER2+ metastatic breast cancer sequencing, maintenance, and trial strategy.

The FDA approves a new formulation of piflufolastat F 18, enhancing prostate cancer imaging with improved efficiency and patient access.

FDA’s February oncology surge brings new pancreatic TTFields, PD-1 win in ovarian cancer, AI tools, and key trial setbacks.

The combination of durvalumab and tremelimumab improved disease-free survival compared with active monitoring but efficacy came with increased toxicity.

Johns Hopkins Medicine develops a free immune atlas of pancreatic cancer trials, spotlighting blood-based signals to build stronger pancreatic cancer immunotherapy combinations.

During a live event, Joshua Richter, MD, explored proactive adverse event management when using selinexor in multiple myeloma.

Hi-C on routine FFPE biopsies uncovers hidden lymphoma drivers, enhancer hijacking, and PD-L1 rearrangements, guiding targeted therapy beyond FISH.

Phase 2a data show oral namodenoson is well tolerated in heavily pretreated pancreatic cancer, with survival follow-up ongoing and FDA orphan status boosting promise.

The FDA granted approval of the combination of teclistamab and daratumumab for patients with 1-3 prior lines of therapy in myeloma.

The FDA has granted a priority review and accepted the NDA for rusfertide in PV.

In an interview, Vincent Ma, MD, discussed how ctDNA levels after the first cycle of immune checkpoint inhibitor in melanoma could shed light on clinical outcomes.

During a live event, Hagen Kennecke, MD, discussed key trials shaping the treatment landscape of PNETs.